Last checked at 4 Mar 2020 15:33
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that it has granted share options ("Options") to members of its senior management team to acquire a total of 2,169,608 ordinary shares of 1.5p each ("Ordinary Shares") in the Company under the Company's Share Option Scheme.
The Options have been granted with an exercise price equal to the close price on the day before the grant and vest after a period of three years, subject to certain performance criteria being met through achieving revenue targets, achieving cash targets and completing certain strategic projects in the year ending June 2022. The Options are exercisable over the period of 10 years from the date of grant.
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
1. | Details of the person discharging managerial responsibilities / person closely associated | |||||||||||||||||||
a. | Name | 1. David Budd 2. Matthew Fowler 3. Gino Miele 4. Gordon Powell 5. Colleen Pythian
| ||||||||||||||||||
2. | Reason for the notification | |||||||||||||||||||
a. | Position/status | 1. CEO 2. CFO 3. R&D Director 4. Commercial Director 5. Director of Quality & Regulation | ||||||||||||||||||
a. | Initial notification /Amendment | Initial notification | ||||||||||||||||||
3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||||||||
a. | Name | genedrive plc | ||||||||||||||||||
b. | LEI | 213800ZYODIRZ87Y4K14 | ||||||||||||||||||
4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||||||||
a. | Description of the Financial instrument, type of instrument Identification code | Options over ordinary shares of 1.5 pence each
GB00B1VKB244 | ||||||||||||||||||
b. | Nature of the transaction | Grant of options pursuant to and in accordance with the terms of the Company's Share Option Scheme dated 29 November 2017 | ||||||||||||||||||
c. | Price(s) and volume(s) |
| ||||||||||||||||||
d. | Aggregated information · Aggregated volume · Price
|
N/A
| ||||||||||||||||||
e. | Date of the transaction | 2020-04-03 | ||||||||||||||||||
f. | Place of the transaction | Outside a trading venue | ||||||||||||||||||
For further details please contact:
genedrive plc | +44 (0)161 989 0245 |
David Budd: CEO / Matthew Fowler: CFO | |
Peel Hunt LLP (Nominated Adviser and Joint Broker) | +44 (0)20 7418 8900 |
James Steel / Oliver Jackson | |
Stanford Capital Partners Limited (Joint Broker) | +44 (0)20 3815 8880 |
Patrick Claridge / John Howes | |
Walbrook PR Ltd (Media Relations & Investor Relations) | +44 (0)20 7933 8780 or genedrive@walbrookpr.com |
Paul McManus / Anna Dunphy | +44 (0)7980 541 893 / +44 (0)7876 741 001 |